Primary<unk>  occurs when excess red blood cells are produced as a result of an abnormality of the bone marrow. Often, excess white blood cells and platelets are also produced.<unk>  is classified as a myeloproliferative neoplasm.<unk>  arises from hematopoietic stem cells, which give rise to erythrocytes cells that are normally involved in delivering oxygen to the body tissue. The incidence of<unk>  is approximately 0.7 to 2.6 per 100,000 individuals in the US. Common risk factors in the development of<unk>  are history of thrombosis and old age ( 65 year old and older). If left untreated, patients with<unk>  may progress to develop headache, fatigue, and dyspnea. Common complications of<unk>  include bleeding, thrombosis, tinnitus , and splenomegaly. Prognosis is generally good with treatment, and the median survival for patients with<unk>  is around 10.9 to 27.8 years. People with<unk>  usually asymptomatic. Symptoms of<unk>  include headache, fatigue, and pruritis. Laboratory findings associated with the diagnosis of<unk>  include erythrocytosis, leukocytosis, andthrombocytosis. The mainstay of therapy for<unk>  is phlebotomy, hydroxyurea (alone or with phlebotomy), interferon-alpha and pegylated interferon-alpha, chlorambucil, and low-dose aspirin.
Polycythemia vera
Aplastic anemia
Essential thrombocytosis
Myelofibrosis
Chronic myelogenous leukemia
Idiopathic thrombocytopenic purpura
Transient erythroblastopenia of childhood
Thrombotic thrombocytopenic purpura